Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 ...

Additionally, a supportive secondary analysis showed that 50.7% of participants with obesity treated with CagriSema reached non-obesity levels (BMI 30 kg/m²) by the end of treatment, down from a mean ...

WASHINGTON (dpa-AFX) - Novo Nordisk's (NVO) Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...